Objective-Venous thromboembolism is a major contributor to global disease burden. Leukocytes and platelets initiate thrombogenesis on blood stasis and initiate the formation of a fibrin, VWF (von Willebrand factor), and neutrophil extracellular trap scaffold for erythrocytes. However, there is little knowledge on how erythrocytes become stably incorporated into this scaffold. Recently, we described the adhesion of calcium-loaded erythrocytes to endothelial-derived VWF strings. Because VWF is part of the scaffold of venous thrombi, we questioned whether reduced flow or stasis promotes the adhesion of normal erythrocytes to VWF and whether venous thrombi show evidence of erythrocyte-VWF interactions. Approach and Results-In the present work, we perfused, under controlled shear conditions, washed, normal erythrocytes over surface-immobilized plasma and extracellular matrix proteins and showed that normal erythrocytes specifically bind to VWF. The interaction between erythrocytes and VWF significantly increased when the wall shear stress was reduced. Next, we investigated whether erythrocyte-VWF interactions support the structure of venous thrombi. High-resolution immunofluorescence imaging of human venous thrombi showed a striking pattern between erythrocytes, VWF, and fibrin, which suggests that VWF plays a supporting role, linking erythrocytes to fibrin in the thrombus. Conclusions-Our data suggest that erythrocyte retention in venous thrombi is mediated by erythrocyte-VWF or erythrocyte-VWF-fibrin interactions. Targeting erythrocyte retention could be a new strategy in the treatment or prevention of venous thrombosis. Visual Overview-An online visual overview is available for this article. 
D
eep vein thrombosis (DVT) and pulmonary embolism, collectively referred to as venous thromboembolism (VTE), are major contributors to global disease burden. 1 VTE represents the third leading vascular disease after myocardial infarction and stroke. [1] [2] [3] Studies from Western Europe, North America, Australia, and Southern Latin America reported overall annual incidences of VTE ranging from 0.75 to 2.69 per 1000 individuals. 1 The global incidence of VTE is likely to increase with improving life expectancy in low-and middle-income countries and an aging population. 1 
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See cover image DVT develops mostly in the lower extremities, but the upper extremities, 4 splanchnic veins, 5 and cerebral veins may also be affected. 6 Venous thrombi are fibrin-and red blood cellsrich red clots and mostly develop in the absence of endothelial injury. 7 Venous valve pockets are the most frequent sites of deep vein thrombogenesis 8, 9 where a hypercoagulable environment, hypoxia, and blood stasis can trigger thrombogenesis. 7, 10, 11 Hypoxia activates endothelial cells and induces Weibel-Palade body exocytosis. 12, 13 Weibel-Palade body-derived P-selectin and VWF (von Willebrand factor) recruit leukocytes, platelets, and tissue factor-positive microparticles. 12, 14, 15 Tissue factorpositive microparticles and monocytes initiate FVII (factor VII)-dependent coagulation, 12, 15, 16 while platelet-neutrophil complexes foster neutrophil extracellular trap formation, which promotes FXII-dependent coagulation. 12, 17 Finally, fibrin, VWF, and neutrophil extracellular traps form a scaffold for platelet and erythrocyte adhesion and promote thrombus formation and growth. 12, 17 FXIII(a) mediates erythrocyte retention in venous thrombi. 18 However, it remains unclear whether erythrocytes themselves become crosslinked to the clot or to fibrin or other clot-bound proteins or cells. 18 Erythrocytes bind to activated neutrophils, activated platelets, and fibrin at reduced shear rates. 18, 19 Recently, we described platelet-independent binding of calcium-loaded erythrocytes to endothelial-derived VWF strings. 20 Therefore, we questioned whether flow reduction would promote the adhesion of normal erythrocytes to VWF and whether venous thrombi show evidence of erythrocyte-VWF interactions.
Here we showed that a reduction of flow promotes erythrocyte adhesion to VWF. Detailed analysis of venous thrombi further showed that erythrocytes are closely associated to fibrin, with clusters of VWF at the erythrocyte-fibrin contact sites. These findings support that reduced flow and stasis stimulates retention of erythrocytes in fibrin-rich venous thrombi through their interaction with VWF.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Erythrocytes Bind Specifically to VWF
To analyze the adhesion of erythrocytes to VWF, flow chambers, coated with surface-immobilized plasma and extracellular matrix proteins, were used. First, the functionality of the substrates was tested using platelet perfusion. Washed platelets bound to VWF, collagen type I, fibronectin, fibrinogen, and fibrin as previously described [21] [22] [23] ( Figure 1A ). In contrast, erythrocytes perfused at a postcapillary venule 24 or venous 25 shear rate only bound significantly to VWF, with limited or no binding to the other substrates ( Figure 1B ). Washed erythrocytes contained virtually no platelets or white blood cells as shown in Table 1 . Finally, although ionomycin-induced calcium-loading of erythrocytes significantly promoted VWF binding, only a limited number of such erythrocytes bound to the other substrates ( Figure 1C ). 
Flow Reduction Promotes Erythrocyte Binding to VWF
Erythrocytes bind activated neutrophils, activated platelets, and fibrin at reduced shear rates. 18 ,19 Therefore, we tested whether flow reduction would also promote the adhesion of erythrocytes to VWF. Erythrocytes were perfused over surface-immobilized proteins at different shear rates (see Table 2 ). Increasing the wall shear stress to ≥1 dyne/cm 2 did not promote erythrocyte adhesion to VWF. In contrast, wall shear stress reduction significantly increased erythrocyte-VWF binding, with limited or no binding of erythrocytes to the control (bovine serum albumin) or other substrates (Figure 2A and 2B; Figure  I and Movie I in the online-only Data Supplement). Wall shear stress reduction <0.5 dyne/cm 2 induced rapid and firm adhesion of many erythrocytes to VWF ( Figure 2C ). Although wall shear stress reduction induced erythrocyte rolling over the control substrate, the absolute number of firmly adherent cells remained low (4%). Wall shear stress reduction also induced erythrocyte rolling over VWF. However, significantly more erythrocytes (82%) remained firmly adherent ( Figure IIA We also tested whether erythrocytes in whole blood would adhere to VWF, and how this adhesion would compare to platelet-VWF adhesion at different wall shear stresses. First, we compared washed erythrocytes to heparin anticoagulated whole blood, citrate anticoagulated whole blood, and recalcified citrate anticoagulated whole blood all diluted to 1% hematocrit. No significant difference in erythrocyte-VWF binding could be observed between washed erythrocytes or whole blood ( Figure 3A) . After perfusion of undiluted citrate anticoagulated whole blood at 0.500 dyne/cm 2 , significant platelet-VWF binding was observed. While platelet binding was reduced at a wall shear stress of 0.250 dyne/ cm 2 , limited erythrocyte binding was observed ( Figure 3B ). Moreover, adherent erythrocytes appeared to be recruited by platelets ( Figure 3B , arrowhead). However, in line with previous results, abundant erythrocyte-VWF adhesion occurred at a wall shear stress of 0.125 dyne/cm 2 ( Figure 3B ). Together, these results show that flow reduction promotes erythrocyte-VWF binding.
Flow Reduction Is More Effective in Promoting Erythrocyte-VWF Interaction Than Calcium Loading
We previously reported that calcium loading promotes erythrocyte-VWF interaction. 20 Therefore, we tested whether calcium loading and flow reduction synergistically promote erythrocyte-VWF binding. Ionomycin-induced erythrocyte-calcium loading induced a reduction in erythrocyte size and phosphatidylserine exposure ( Figure IV in the online-only Data Supplement) and significantly enhanced erythrocyte-VWF binding at a wall shear stress of 1 and 0.5 dyne/cm 2 ( Figure 4A ). However, below 0.5 dyne/cm 2 , this additive effect was not significant anymore ( Figure 4A ). Inhibiting the ionomycin-induced intracellular calcium increase by EGTA preincubation prevented phosphatidylserine exposure and reduced erythrocyte-VWF adhesion ( Figure 4B ). Flow reduction combined with ionomycin-induced calcium loading caused only limited binding to other substrates (Figures V and VI in the online-only Data Supplement). A similar response was observed when a calcium influx was induced using lysophosphatidic acid (LPA), which also could be prevented by EGTA preincubation ( 
Erythrocyte-VWF and Fibrin-VWF Complexes Are Prominently Present in Human Venous Thrombi
Blood stasis is an important risk factor for DVT, and venous thrombi are rich in erythrocytes 7 ; therefore, we addressed whether erythrocyte-VWF complexes are present in human venous thrombi. First, VWF localization was analyzed within venous thrombi. Demographic and clinicopathological characteristics of patients are given in Table 3 . Slides were stained with Elastica von Gieson stain, VWF, GLUT1 (a marker for . These data suggest that erythrocytes may interact with VWF in venous thrombi. For higher resolution imaging and to investigate whether erythrocytes interact with VWF, sections of the same thrombus were immunofluorescently stained for CD42b (staining platelets) and VWF. Erythrocytes were visualized based on their autofluorescence. 26 Figure 5A shows several erythrocyte-rich thrombi within an arteriovenous malformation. The thrombus showed only limited CD42b (platelets) staining, but large sections stained positive for VWF and erythrocytes ( Figure 5C ). VWF was nonuniformly distributed throughout the thrombus. Areas positive for both VWF and CD42b (region I), positive for VWF but negative for CD42b (region II), intermediate positive for VWF (region III), and low positive for VWF (region IV) could be distinguished (Figure 5D and 5E; Figure  VIII 
Discussion
Venous thrombus size is primarily determined by erythrocyte content. 18 However, there is little knowledge on how erythrocytes become stably incorporated into the scaffold built from fibrin, VWF, and neutrophil extracellular traps. 27 In the present study, it was demonstrated that under reduced wall shear stress, erythrocytes specifically bind to VWF. Furthermore, imaging of venous thrombi showed a striking pattern of erythrocytes, VWF, and fibrin, which suggests that VWF has a supporting role in the structure of venous thrombi by forming erythrocyte-erythrocyte and erythrocyte-fibrin links. Erythrocytes are actively retained within a thrombus during thrombogenesis. 18 The transglutaminase factor XIII is crucial for red blood cell retention in clots. 18 Fibrinogen γ-chain residues 390 to 396 mediate FXIII-A 2 B 2 binding and activation. 18 Fibγ 390-396A mice developed smaller thrombi with fewer erythrocytes than thrombi from wild-type mice in an inferior vena cava stasis model. 18 The smaller thrombus size was explained by reduced erythrocyte retention during clot retraction. 18 Inhibiting FXIIIa increased erythrocyte mobility and extrusion from contracting clots. 28 Factor XIIIa evidently contributes to erythrocyte retention during thrombogenesis; however, FXIIIa was not able to crosslink erythrocytes directly to fibrin. 28 Secondary to fibrin, >147 plasma proteins serve as a substrate for FXIIIa. 29 VWF, with 12 identified reactive glutamine residues, is one of the proteins that has been identified as a FXIIIa substrate. 29, 30 VWF was shown to be covalently associated with plasma clots through the fibrin α-chain. 29, 30 In the present study, we showed that VWF localizes in and around fibrin-rich regions of venous thrombi. VWF crosslinked to fibrin could improve erythrocyte retention because erythrocytes showed strong and abundant adhesion to VWF at reduced shear rates, which are in the range of those in venous valve pockets and are associated with venous thrombogenesis. 27, 31 A large number of risk factors for VTE has been identified. These include cancer and major surgery but also increased levels of coagulation factors, particularly factor VIII, prothrombin, and VWF. 32, 33 The important role for VWF in DVT was shown by the protection from thrombosis of VWF (−/−) mice in an inferior vena cava stenosis model.
14 Infusion of recombinant factor VIII did not rescue thrombosis in VWF (−/−) mice; impaired coagulation was, therefore, not the reason these mice did not develop DVT.
14 Furthermore, venous thrombosis rarely appears in patients with von Willebrand's disease, and the majority of patients who developed a venous thrombotic manifestation received substitution therapy with FVIII/ VWF concentrates. 34 VWF is important in the initiation state of venous thrombotic events by recruiting platelets and leukocytes, 12, 14 but our data show that VWF can play an additional important role during thrombus propagation by promoting erythrocyte retention at sites of reduced flow.
While platelets can bind to collagen, 21 fibronectin, 21 fibrinogen, 22 and fibrin, 23 erythrocytes in our study showed little binding to substrates other than VWF. Contradicting results have been published about erythrocyte-fibrin(ogen) binding. It has been shown that erythrocytes can bind fibrin(ogen) at reduced shear rates, 27,35 though it is not clear if this occurs via direct binding or that additional plasma proteins recruit erythrocytes to fibrin(ogen). 19 Although this study confirmed adhesion of erythrocytes to fibrin(ogen), the number of adherent cells was limited. The large difference observed in absolute numbers between erythrocytes binding to fibrin(ogen) and erythrocytes binding to VWF suggests that at reduced shear rates erythrocytes preferentially bind to VWF.
How erythrocytes interact with VWF is as yet unknown. Interestingly, although an increase of wall shear stress promotes platelet adhesion to VWF, 36 this study shows that the adhesion of erythrocytes to VWF is promoted by a reduction in wall shear stress. This mechanism could be a fundamental difference between white arterial thrombi, which are formed at high shear stress and consist mainly of platelets, and red venous thrombi, which are formed at low shear stress and consist mainly of erythrocytes. This also suggests that the erythrocyte receptor for VWF differs from the high-affinity receptors for VWF on platelets. We screened erythrocytes for the presence of the integrins αV, β1, β2, and β3, with endothelial cells or leukocytes as positive controls, and none of them could be found. Erythrocytes were also negative for GPIbA (the platelet glycoprotein Ib alpha chain) and P-selectin (data not shown). All these findings are in line with previous results. 37 To find a possible receptor that mediated erythrocyte-VWF adhesion, we applied a blocking strategy on potential erythrocyte-specific VWF receptors. Blocking Lu/BCAM (the erythrocyte basal cell adhesion molecule) using a highly specific antibody which blocks erythrocyte binding to Laminin, α5 did not interfere with the erythrocyte-VWF interaction. Also blocking CD44 with hyaluronic acid did not interfere with erythrocyte binding to VWF (data not shown). Besides the striking difference in VWF adhesion between erythrocytes and platelets based on the wall shear stress and, thereby, the involved receptors, the multimer size of VWF may also represent another difference in erythrocyte adhesion versus platelet adhesion. Where platelets are known to preferentially bind to high molecular weight VWF, 36 our data suggest erythrocytes-preferred intermediate molecular weight VWF. This indicates that erythrocytes may be less likely to adhere to the ultra large VWF multimers released by platelets and endothelial cells, which are important in hemostasis and arterial thrombosis, but likely first need ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13)-mediated proteolysis of VWF before adhesion. It would be of interest to see if the ADAMTS13-mediated, proteolytic cleaved VWF multimers would also bind erythrocytes in the circulation, which could, thereby, contribute to the rapid clearance of VWF.
Whether erythrocytes, similar to platelets, adhere to the A1 domain of VWF is not known. The whole blood assay suggests competition between platelet and erythrocyte adherence. Platelets preferred shear stresses of ≥0.250 dyne/cm 2 for VWF adherence, while erythrocytes bind at a shear stress of ≤0.250 dyne/cm 2 . Caution should be taken as the immobilized VWF is likely unfolded during the coating process, which causes the exposure of the A1 domain, which promotes platelet recruitment. Whether erythrocytes also need this unfolding and A1 domain exposure or whether they can bind to globular VWF needs to be determined. However, erythrocytes prefer low shear stress, which makes VWF less susceptible for unfolding, suggesting that erythrocytes could bind to VWF while it is still in its globular conformation.
Besides the effects of different shear forces on the erythrocyte-VWF interaction, this study also described that the erythrocyte-VWF interaction could be enhanced via an LPAinduced calcium influx into erythrocytes. LPA can be formed via the autotaxin-LPA axis on activated platelets. 38 In good agreement, platelets have been described to be essential for venous thrombogenesis. 12, 14 Although LPA promoted erythrocyte adhesion to VWF, it did not induce phosphatidylserine exposure on the erythrocyte membrane as seen in the ionomycin-treated cells. Therefore, phosphatidylserine exposure may contribute to VWF adhesion but seems unlikely to be the main cause of binding. How calcium loading enhances erythrocyte adhesion to VWF remains unclear, but these data suggest the presence of an intrinsic signaling cascade that affects potential VWF receptors on the erythrocytes.
Finally, this study has potential limitations. Even though the in vitro immobilized VWF assay cannot fully represent the microenvironment of an in vivo developing thrombus, it does provide a clean method to investigate erythrocyte-VWF interaction. Moreover, the whole blood assay and the venous thrombi sections suggests that the erythrocyte-VWF interaction can occur in vivo. However, the human venous thrombi tissue sections represent the end result of an in vivo developed thrombus, which provides descriptive information but limited insight into mechanisms driving thrombogenesis. Nevertheless, these data strongly suggest erythrocyte-VWF and fibrin-VWF interactions, which may play a supportive role in these thrombi. Finding the erythrocyte receptor that mediates VWF binding and targeting these receptors in an in vivo venous thrombosis model would uncover the role of erythrocyte-VWF interaction in venous thrombosis.
To conclude, our data demonstrate that under reduced wall shear stress, erythrocytes specifically bind to VWF, which suggests that VWF plays a supporting role in the structure of venous thrombi by forming erythrocyte intercellular links and erythrocyte-fibrin links. A larger venous thrombus size is associated with increased morbidity and mortality and results in increased recurrence of VTE. 39 Venous thrombosis is treated by targeting the coagulation cascade. 40, 41 However, the main side effect of anticoagulant therapy is bleeding. 40, 41 Our study suggests that erythrocyte retention in venous thrombi could, in addition to fibrin network stiffness, be mediated by erythrocyte-VWF or erythrocyte-VWF-fibrin interactions. If the erythrocyte-VWF interaction proves to significantly contribute to the structural integrity of venous thrombi, targeting erythrocytes, instead of the coagulation cascade, could not only provide novel intervention strategies but also minimize bleeding.
